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examination of trajectory patterns of patient-level health care costs. The model
was adjusted for baseline demographics, Charlson comorbidity index (CCI), body
system index (BSI), and prior medication index (PMI). Rates of change (slopes) were
estimated from the fitted model and differences in the cost trajectory patterns
among dosing cohorts were tested using F-test. Bootstrapping was used to provide
a sensitivity analysis. RESULTS: A repeated measures linear mixed model with
dose, month, and dose*month as fixed effects and patient, patient*dose as a ran-
dom effects, adjusting for demographics, CCI, BSI, and PMI, was developed. Main
effects and covariates were all significant (all p.05). The model revealed that total
health care costs increased sharply in the months leading up to, and decreased in
the months following, initiation of duloxetine treatment for each dosing cohort
and the overall cohort (all p.05). Compared to patients given low- or standard-
dose therapy, patients who received high-dose duloxetine had higher health care
expenses both prior to and following initiation of duloxetine therapy (p.05). Boot-
strapping confirmed the above test results. CONCLUSIONS: Longitudinal models
provide great opportunities to assess changes in cost trajectory patterns around the time
ofchanges inmedical treatmentcomparedtothecurrentstandardmeanmethods. Inthis
analysis, health care costs increased prior to the initiation of duloxetine therapy, perhaps
signaling a clinical deterioration that led to a change in treatment strategy. Health care
costs then decreased following initiation of duloxetine treatment.
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OBJECTIVES: To evaluate the health care and productivity costs in patients with
generalized anxiety disorder (GAD) before and after the initiation of a SSRI
(selective serotonin re-uptake inhibitor), a SNRI (serotonin norepinephrine re-
uptake inhibitor), benzodiazepine or pregabalin. METHODS: Patients with an
ICD10-code F40-F41 and at least two prescription claims for either SSRI, SNRI,
benzodiazepin or pregabalin were identified using data from the Danish Na-
tional Patient Registry, the Psychiatric Central Registry, the Medicinal Registry
and other registries (2006-2010). Patients identified with neuropathic pain were
excluded. The index date was considered the first prescription for SSRI, SNRI,
benzodiazepines or pregabalin. Descriptive assessments of health care and pro-
ductivity costs were conducted 12 months pre and post the index date using the
full dataset, whereas a sub-analysis focussed on F41.1 (GAD). To control for
selection bias, a propensity score matched cohort controlling for age, gender,
Charlson score, depression, alcoholism, socioeconomic and cohabit status, and
health care resource use was also conducted. Statistical tests performed were
Wilcoxon (0.05). RESULTS: A total of 18,357 (F40-F41) patients met the inclu-
sion criteria (treatment courses included: 14,095 SSRI; 5,035 SNRI; 8,580 benzo-
diazepines; 1,628 pregabalin). Twelve months health care costs were only sig-
nificantly reduced in the pregabalin group (€1,285; P0.001). The three other
groups resulted in significantly increased health care costs (€808-€1,548;
P0.001). Similar results were found focusing only on F41.1; however insignifi-
cant for pregabalin. Matched sub-analyses covering 1,588 patients in each group
showed similar significant reduced 12 months health care costs in the SNRI and
pregabalin groups (P0.001). Across all four groups the ability to retain employ-
ment was significantly improved, whereas long-term sickness increased; how-
ever, insignificantly so in the pregabalin group. CONCLUSIONS: Health care
costs 12 months after the initiation of the treatment with pregabalin were sig-
nificantly reduced. Besides pregabalin, this was in matched analyses also the
case for the SNRI group. Production loss did not differ between groups.
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OBJECTIVES: A 2005 systematic review identified no cost-effectiveness studies
in paediatric bipolar disorder (PBD). Following a recent surge in clinical research
on the use of atypical antipsychotics in this area, an update of the review is
necessary to inform economic models. The current systematic review objective
was to identify all literature published since 2005 on economic aspects of PBD.
METHODS: EMBASE, MEDLINE, PsychINFO, CINAHL, EconLIT, and NHSEED were
systematically searched from 2005 to January 2012. Articles were included if
they reported an economic evaluation (cost-minimisation, cost-effectiveness,
cost-utility or cost-benefit study), details of costs of care, resource use, health-
related quality of life (HRQoL) or utilities for patients aged 18 years with bipo-
lar disorder. No limits were put on language or country. Full texts of potentially
relevant articles were obtained and assessed against the same inclusion crite-
ria. Reference lists and congress abstracts were also searched. RESULTS:Of 5388
search results, 104 were deemed potentially relevant. After review of full texts,
5 studies were included that reported HRQoL data for bipolar patients 18yrs.
No articles were found that reported on economic evaluations, costs of care,
resource use or utilities for PBD. Two congress abstracts reported PQ-LES-Q
values from an aripiprazole RCT and 1 reported CHQ-PF50 from a quetiapine
RCT. Both treatments were found to improve HRQoL, but the difference from
placebo did not reach significance for aripiprazole over the 4 week trial. Other
studies found that PBD was associated with significantly lower HRQoL than
other common childhood conditions and that HRQoL might be more affected by
depressive than manic symptoms. CONCLUSIONS: Despite the increase in the
number of clinical trials on treatments for paediatric bipolar disorder, there are
currently no published cost-effectiveness studies, cost/resource use data or
utilities. These data will be required to inform reliable cost-effectiveness mod-
els of treatments in this field.
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OBJECTIVES: In Germany, about 500,000 people suffer from Schizophrenia. Due to
its chronic relapsing course that involves fundamental functional and social im-
pairment, schizophrenia has emerged as a dominant burden to society. However,
studies to determine the economic consequences of the disease have largely been
carried out in clinical settings based on a relatively small number of cases. There-
fore we aim to assess the medical and non-medical consequences of schizophrenia
as well as the cost structure across treatment settings and population characteris-
tics using administrative data. METHODS: Costs attributable to Schizophrenia
were estimated using a case-control design, where 26,294 patients drawn from a
sickness fund administrative database were matched to 9,319 patients with a con-
firmed diagnosis of schizophrenia (ICD-10: F20). To obtain balance between both
groups in a set of observed pre-treatment variables (age, sex, prior number of drug
prescriptions, Elixhauser comorbidities) and to reduce the conditional bias, a ge-
netic matching algorithm was employed. Eventually, costs and other health care
resource utilization parameters for cases and controls were recorded during 2008.
RESULTS: The annual cost attributable to Schizophrenia amounts to € 10610 per
patient from the payer’s perspective, and € 19927 from the societal perspective.
Lost productivity (46.6%), inpatient treatment (29.0%) and nursing care (14.3%) are
the major cost drivers of the disease. The burden of disease of Schizophrenia in
Germany is estimated to be approximately € 5220 million per year from the sick-
ness fund perspective and € 9804 million from the societal perspective.
CONCLUSIONS: While our calculations still underestimate the true burden of dis-
ease due to restricting quality of life to production forgone and due to ignoring the
impact on family members, considerable direct and indirect costs of schizophrenia
highlight the need for further research in order to improve care patterns and to find
innovate treatment solutions.
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OBJECTIVES: Schizophrenia places a heavy burden on individuals and their care-
givers, as well as potentially placing a large demand on the health care system and
its resources. The objective was to understand the cost burden imposed by schizo-
phrenia, and to identify the key drivers of costs. METHODS: We conducted a liter-
ature review capturing reviews and recent individual studies on costs of the dis-
ease in Europe and US, using Embase and Medline databases. RESULTS: Thirty-six
references were included, covering 8 countries (UK, France, Germany, Norway,
Canada, US, India and Thailand). Costs described were mainly those related to care
settings (hospital or community), pharmacological and non pharmacological ther-
apies, comorbidities and family or caregiver costs. The absolute costs were variable
across studies (e.g. from €5,000 to €12,000 per year in England, from $8,000 to
$26,000 per year in Canada and from 86,000THB to 146,000 THB in Thailand). This
was due primarily to the differences in the national health care system, but also to
the type of costs included in the analyses. Key drivers of costs included gender
(male patients were about 50% more costly), type of medication, and previous
psychiatric hospital admission. Costs also increased with severity of the disease.
CONCLUSIONS: The burden of schizophrenia is significant regardless of the coun-
try; however variable estimates of the burden are available in literature due mainly
to the treatment regimens used and the approaches to schizophrenia care (e.g.
hospital based versus community-based) in respective countries. At present, there
is a need of a standard method for quantitatively assessing and aggregating the
various aspects of the cost of schizophrenia.
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OBJECTIVES: Schizophrenia is a chronic and disabling severe mental disorder
with considerable economic importance. Detailed estimates of treatment pat-
terns and costs of outpatient and inpatient treatment of patients with schizo-
phrenia are an important input factor for health economic cost-effectiveness
models. Up to date there are several publications which assess the treatment
patterns and costs of schizophrenia in Germany. However, most of the infor-
mation is limited as an input for cost-effectiveness models due to the fact that
differentiated micro information about the frequency of contacts in different
treatment areas and costs of a single contact are missing. Therefore, we exam-
ine the treatment patterns and micro costs of treatment of schizophrenia re-
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flecting real-life clinical practice based on structured interviews with experts.
METHODS: Six experts in the field of schizophrenia from different treatment
settings and regions in Germany were consulted. Structured interviews about
the treatment patterns and costs in selected outpatient and inpatient treatment
areas, e.g. psychiatrists, occupational therapists, day care units and acute psy-
chiatric wards, were conducted. Costs were assessed from the perspective of the
statutory health insurance. The assessment was divided into stable and relaps-
ing schizophrenic patients. Costs for the management of frequent side effects
were considered. RESULTS: The proportion of stable patients with schizophre-
nia was assessed to be 80% in Germany. Stable patients were estimated to have
1.5 psychiatrist contacts per quarter and relapsing patients were assessed to
have 6-8 contacts per quarter. Psychiatrist costs per quarter are varying be-
tween different regions in Germany, e.g. costs in Bavaria were €92 in 2011.
Inpatient costs per day in acute psychiatric wards are varying between €206 in
Baden-Württemberg and €244 in Saarland. CONCLUSIONS: The results of the
structured expert interviews will be used as input for cost-effectiveness models
in schizophrenia. In further studies the results should be verified in real-life
clinical practice.
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OBJECTIVES: Only few people with severe mental illness are able to obtain paid
work. Individual placement and support (IPS) is a vocational rehabilitation inter-
vention aimed at assisting people with severe mental illness in finding competitive
employment. This study assessed the balance between costs and outcomes of IPS
compared to regular vocational rehabilitation in people with severe mental illness
in the Netherlands. METHODS: An economic evaluation was conducted alongside
a multicenter RCT with a follow-up of 30 months. In total 151 people with severe
mental illness were randomly assigned to IPS or regular vocational rehabilitation-
(RVR). The primary outcome measure of the cost-effectiveness analysis was the
percentage of people with at least one day of paid work during the study. The
economic evaluation was conducted from a societal perspective. Costs and out-
comes were prospectively assessed during 30 months. The expectation maximisa-
tion algorithm with a bootstrap approach was applied to deal with missing cost
data. RESULTS: The percentage of people with paid work during the study was
significantly higher in the IPS group (44% versus 25% in RVR). There were no differ-
ences between groups in quality of life. Mean total costs were €57,285 in the IPS
group and €43,819 in the RVR group. Cost types that contributed considerably to the
total costs were related to hospital admissions, sheltered accommodations, and
informal care. The calculated incremental cost-effectiveness ratio was €1,084 per
percent of people with paid work gained. CONCLUSIONS: The study demonstrated
that IPS was associated with higher costs and better (work-related) outcomes in
people with severe mental illness. Decision makers will eventually have to decide
whether the described gains associated with IPS are worth the additional costs.
Generalizing current results to other countries may only be possible after carefully
comparing the various components of each health care system concerned.
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OBJECTIVES: Metabolic syndrome (MetS) is a medical condition that may arise
during exposure to antipsychotics and carries with it an increased risk of diabetes
and cardiovascular disease (CVD). Asenapine is the first tetracyclic antipsychotic to
treat manic episodes of Bipolar I Disorder (BD- I). In a head-to-head non-inferiority
trial versus olanzapine, post-hoc analyses illustrate the higher incidence of devel-
oping MetS with olanzapine than with asenapine, already after 12 weeks of treat-
ment. The aim of this study was to assess the cost-effectiveness of asenapine in the
treatment of BD-I manic episodes compared to atypical antipsychotics with a focus
on the long-term consequences of MetS over lifetime horizon. METHODS: A
Markov health-state cohort model was developed. Because similar efficacy in treat-
ing manic episodes was demonstrated in active controlled non-inferiority clinical
trial vs. olanzapine and through indirect comparisons with quetiapine and arip-
iprazole, only the consequences of MetS were considered for this model. The risks
of developing MetS after 12 weeks of treatment were derived from randomized
clinical trials. The subsequent risks of developing diabetes or cardiovascular dis-
ease were based on previously published risk models. The perspective of the UK
National Health Service (NHS) was applied and a lifetime horizon adopted. Deter-
ministic and probabilistic sensitivity analyses were conducted. RESULTS: Asenap-
ine dominates (more effective and less expensive) olanzapine, quetiapine and arip-
iprazole over lifetime horizon. Compared to treatment with generic olanzapine,
and branded aripiprazole and quetiapine, asenapine was associated with incre-
mental total costs of -£121, -£312 and -£560 respectively. Asenapine was associated
with Quality-Adjusted Life Year gains of 0.0569 compared to olanzapine and que-
tiapine, and 0.0038 compared to aripriprazole. CONCLUSIONS: The significant
lower incidence of developing MetS associated with asenapine compared to olan-
zapine, aripriprazole and quetiapine is associated with a lower incidence of diabe-
tes and CVD that results in lower subsequent treatment costs and improved mor-
bidity.
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OBJECTIVES: Acute agitation is a transient syndrome characterized by increase in
verbal and physical behavior, which results in aggression. In order to diminish the
risk of damage for both, caregivers and patients, fast response drugs are required.
The study is aimed to estimate the pharmacoeconomic profile of intramuscular
injections of haloperidol 5mg, olanzapine 10mg and ziprasidone 20mg for acute
agitation episodes associated with schizophrenia, from the perspective of a Mexi-
can public health institution. METHODS: A discrete event simulation model was
developed. The measure of effectiveness was the average time in which patients
reach control50%, regarding baseline level in the Overt Aggression Scales, with a
time horizon of 12 hours. Clinical efficacy was extracted from published literature.
A panel of experienced psychiatrists (n12) was used to estimate the medical
resource use profile. The model assesses direct medical costs (2012 US$) such as
drugs, specialist’s visits, laboratory tests and management of adverse events. The
results are reported in terms of ICER. Deterministic and probabilistic sensitivity
analyses were performed. RESULTS: The cost per patient for ziprasidone was $693,
it represents $198.6 and $64.6 less than the cost of haloperidol and olanzapine,
respectively. Differences in costs were driven by less specialist’s visits with ziprasi-
done and high incidence of akathisia and dystonia with haloperidol. The effective-
ness measure was accomplished by ziprasidone, olanzapine and haloperidol at
1.55h, 1.48h and 1.74h, respectively. Both ziprasidone and olanzapine dominated
haloperidol. Results were robust to changes up to10% in the acquisition cost of ziprasi-
done. Inprobabilisticsensitivityanalysis, resultswereconsistentwithbasecase,although
differences between ziprasidone and olanzapine were slighter.CONCLUSIONS: In com-
parison to olanzapine and haloperidol, ziprasidone is associated to the lowest costs
in the treatment of acute agitation episodes in schizophrenic patients in the Mex-
ican setting, as well as better clinical performance than haloperidol.
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OBJECTIVES: We conducted a pharmacoeconomic analysis to determine the cost-
effectiveness of atypical antipsychotic long acting treatments in Croatia.
METHODS: A 1-year decision-analytic framework modeled drug use in chronic
schizophrenia. We determined the average direct cost to the Croatian Institute for
Health Insurance of using treatment pathways that includes depot formulations of
paliperidone (PP-LAI), risperidone (RIS-LAI) or olanzapine (OLZ-LAI) long acting
treatments. The decision tree was populated with guidance from an expert panel
along with literature-derived clinical rates. Costs were obtained from published
lists and adjusted to 2012 euros using the Croatian consumer price index. Clinical
outcomes included quality-adjusted life-years (QALYs), hospitalization rates,
emergency room treatment rates, and relapse days. The outcome of interest was
the incremental cost/QALY gained. RESULTS: Total direct costs to treat one patient
for one year were €4958 for PP-LAI, €5117 for RIS-LAI, and €6429 for OLZ-LAI. Re-
spective QALYs were 0.817, 0.805 and 0.812. PP-LAI dominated the other choices as
it had a lower cost and higher QALY score. PP-LAI was associated with 34.5 relapse
days, 0.252 hospitalizations and 0.127 emergency room visits; OLZ-LAI had 38.4
relapse days, 0.280 hospitalizations and 0.142 emergency room visits; RIS-LAI had
41.1 relapse days, 0.305 hospitalizations and 0.146 emergency room visits. Results
were sensitive against RIS-LAI with respect to drug costs (i.e., if PP-LAI cost in-
creased by 10% or RIS-LAI decreased by 14%) and to OLZ-LAI (i.e., a 10% change for
either drug) with respect to adherence rates. Overall, results were generally robust;
PP-LAI dominated OLZ-LAI in 72.2% of 10,000 Monte Carlo simulations and domi-
nated RIS-LAI in 87.8%. CONCLUSIONS: PP-LAI was the cost-effective choice which
dominated the others for treating chronic schizophrenia in Croatia. Using depot
paliperidon would reduce the overall costs of caring for SCH patients.
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OBJECTIVES: We determined the cost-effectiveness of long-acting antipsychotic
(LAI) drugs paliperidone palmitate (PP-LAI), olanzapine pamoate (OLZ-LAI) and ris-
peridone (RIS-LAI) for chronic schizophrenia. METHODS: We adapted a decision
tree analysis from Norway for the Finnish National Health Service. Country-spe-
cific data were sought from the literature and public documents, guided by clinical
experts. Costs of health services and products were retrieved from literature
sources and current price lists. We estimated average costs for treating patients
with each LAI for one year, average remission days, rates of hospitalization and
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